Compare Incyte Corporation (INCY) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Synopsys, Inc. — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while Synopsys, Inc. trades at $389.04 (market cap $72.47B). The key difference: Synopsys, Inc. is far larger — about 3.1× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | SNPS | |
|---|---|---|
Market Cap | $23.11B | $72.47B |
Sector | Health | Technology |
52-Week High | $118.52 | $645.59 |
52-Week Low | $67.38 | $378.46 |
Enterprise Value | $19.13B | $80.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Synopsys (SNPS) trades at $378.47, down 1.51% amid a semiconductor sector downturn. The stock shows bearish technical signals but maintains strong fundamentals with consistent earnings beats and a high analyst buy consensus of 82.76%. Recent news highlights the company's strategic pivot to AI design tools and margin expansion following the Ansys integration.
Outlook remains positive long-term due to SNPS's critical role in AI chip design, though near-term risks include sector volatility and execution of high-margin transitions. The consensus price target of $559.50 implies significant upside, but investors should monitor competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
